By Doug Macron

Silence Therapeutics this week announced that it has put on hold the development of its preclinical cancer drug Atu137 after determining that the drug's potential clinical profile is “too similar” to the company's phase I solid tumor therapy Atu027.

As a result, the firm said it will shift its attention onto an as-yet undisclosed preclinical candidate that makes use of another one of its proprietary delivery technologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.